TABLE 3.
Comparison of change in NT-ProBNP, 6 MWD and LVEF between BYHW and control groups after 3 months of treatment.
| BYHW (n = 34) | Control (n = 33) | p value | |
|---|---|---|---|
| NT-ProBNP (pg/ml) | |||
| Before treatment | 2017.67 ± 3,094.69 | 1954.26 ± 2,690.37 | 0.904 |
| After treatment | 1,211.03 ± 1,663.36** | 1931.23 ± 4,307.86* | 0.406 |
| Proportion of patients with a reduction in NT-proBNP at least 30% (%) | 76.00% | 48.10% | 0.039 |
| LVEF (%) | |||
| Before treatment | 41.09 ± 8.05 | 42.22 ± 7.85 | 0.563 |
| After treatment | 49.12 ± 9.82** | 47.62 ± 10.25** | 0.543 |
| 6 MWD (m) | |||
| Before treatment | 372.10 ± 85.24 | 363.82 ± 97.72 | 0.712 |
| After treatment | 435.91 ± 68.62** | 399.88 ± 126.03* | 0.149 |
NT-proBNP, N-terminal pro-B-type natriuretic peptide; LVEF, left ventricular ejection fraction; 6 MWD, 6-minute walking distance; compared with the same group before treatment, *p < 0.05, **p < 0.01.